Biomedical Engineering Reference
In-Depth Information
TABLE 9.1 Cytokine Traps in Clinical Development and as Approved Therapeutics
Generic
Name
Fusion
Mechanism of Action
Approved Indications
Exploratory Indications
TNFR-Fc
[46,55,60]
Etanercept
Inhibition of TNF- a and
TNF- b /lymphotoxin
[55]
Moderate to severe rheumatoid
arthritis (RA) [61]
Moderate to severe
polyarticular juvenile
idiopathic arthritis (JIA)
Psoriatic arthritis; Ankylosing
spondylitis (AS);
Moderate to severe plaque
psoriasis
Multiple studies for a variety of different
conditions are ongoing
IL1 Trap
Rilonacept
Inhibition of IL1A and
IL1 b [53,62]
Cryopyrin-associated periodic
syndromes (CAPS),
specifically familial cold-
induced autoinflammatory
syndrome (FCAS), and
Muckle-Wells syndrome
(MWS) [63,64]
Gout (NCT00855920; NCT00856206;
NCT00829829; NCT00610363)
Familial Mediterranean Fever
(NCT00582907);
Systemic juvenile idiopathic arthritis
(NCT00534495);
Diabetes mellitus type 1 (NCT00962026);
Schnitzler syndrome (NCT01045772)
VEGFP Trap-Eye Aflibercept
Inhibition of VEGFA and
other VEGF family
members and PGF [65]
None
Phase III for diabetes mellitus macular
edema (NCT01331681); Phase III for
diabetic macular edema (NCT01363440);
Phase III for pathologic myopia
(NCT01249664)
VEGF Trap
Aflibercept As above
None
Multiple Phase I trials for oncologic
indications (NCT00650923,
NCT01148615); multiple Phase II trials in
oncologic indications (NCT00357760;
NCT00437034; NCT00509249;
NCT00828139; NCT01258855)
CD58-IgG1
Alefacept
Exact mechanism
remains to be
deciphered; mixed
agonist/antagonist;
decrease in effector
memory T cells
[66-68]
Chronic moderate to severe
plaque psoriasis [69-73]
Pilot study for allogeneic hematopoietic
stem cell transplantation
(NCT01319851); Phase I for aplastic
anemia (NCT01267643); Phase I for de
novo kidney transplant (NCT01163799);
Phase I/II for resistant chronic graft-
versus-host disease (NCT00397332);
Phase II for chronic graft-versus-host
disease (NCT01226420); Phase II for
diabetes mellitus, type 1 (NCT00965458);
Phase III for kidney transplantation
(NCT00543569); Phase III for graft
versus host disease (NCT00361413)
CTLA4-Ig
Abatacept
Inhibition of the CD28-
CD80/86-mediated co-
stimulatory signal
required for T-cell
activation [74]
Rheumatoid arthritis [75];
juvenile idiopathic arthritis
[76,77]
Phase I for relapsing polychondritis
(NCT01272856); Phase II for acute graft
versus host Disease (NCT01012492);
Phase II for giant cell arteritis and
Takayasu's arteritis (NCT00556439);
Phase II for lupus nephritis
(NCT00774852); Phase II for
polymyositis and dermatomyositis
(NCT01315938); Phase II for Alopecia
totalis or Alopecia universalis
(NCT01314495); Phase II for uveitis
(NCT01279954); Phase II for relapsing-
remitting multiple sclerosis
(NCT01116427); Phase II for asthma
(NCT00784459)
Search WWH ::




Custom Search